Royal Bank of Canada Reaffirms Outperform Rating for Hookipa Pharma (NASDAQ:HOOK)

Royal Bank of Canada reiterated their outperform rating on shares of Hookipa Pharma (NASDAQ:HOOK) in a research note published on Monday, Benzinga reports. The brokerage currently has a $5.00 target price on the stock.

Separately, HC Wainwright reiterated a buy rating and set a $6.50 price objective on shares of Hookipa Pharma in a research report on Monday.

Hookipa Pharma Stock Performance

Shares of HOOK opened at $0.72 on Monday. Hookipa Pharma has a 12-month low of $0.41 and a 12-month high of $2.05. The stock has a market cap of $60.48 million, a P/E ratio of -0.82 and a beta of 1.03. The company has a 50-day moving average of $0.70 and a two-hundred day moving average of $0.63.

Institutional Investors Weigh In On Hookipa Pharma

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new position in Hookipa Pharma in the fourth quarter valued at $43,000. Virtu Financial LLC purchased a new position in shares of Hookipa Pharma in the 2nd quarter worth $47,000. Two Sigma Investments LP acquired a new position in Hookipa Pharma in the third quarter valued at $51,000. Mirabella Financial Services LLP acquired a new position in Hookipa Pharma in the first quarter valued at $82,000. Finally, Alyeska Investment Group L.P. purchased a new stake in Hookipa Pharma during the fourth quarter valued at about $103,000. Institutional investors and hedge funds own 63.88% of the company’s stock.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.